Table 1.
List of CAR-T therapies available
| Product | Company | Approve times | Target | Indications | Price |
|---|---|---|---|---|---|
| Kymaiah | Novartis | 2017 | CD19 |
B-cell non-Hodgkin's lymphoma that failed first- or second-line therapy Acute lymphoblastic leukemia |
$475,000 |
| Tecartus | Gilead | 2020 | CD19 | $373,000 | |
| Yescarta | Kite | 2021 | CD19 | Large B-cell lymphoma or follicular lymphoma | $373,000 |
| Breyanzi | BMS | 2021 | CD19 | B-cell precursor acute lymphoblastic leukemia | $410,300 |
| Abecma | BMS and Bluebird Bio | 2021 | CD19-BCMA | Relapsed and refractory large B-cell lymphoma after second-line or above systemic therapy | $438,000 |
| Akilence | Fosunkite | 2021 | CD19 | Specific non-Hodgkin's lymphoma | ¥1,200,000 |
| JCAR014 | WuXi Junuo | 2017 | CD19 | Aggressive B-cell non-Hodgkin’s lymphoma (NHL) | – |